243 | REAL‐WORLD OUTCOMES OF CD20xCD3 BISPECIFIC ANTIBODY THERAPY IN ADULT PATIENTS WITH RELAPSED/REFRACTORY TRANSFORMED INDOLENT LYMPHOMA
P. Stéphan(Dana-Farber Cancer Institute), Alexey V. Danilov(City of Hope), Robert Redd(Harvard University), Amrita Chauhan(Unknown), Yazeed Sawalha(Cleveland Clinic), Alex F. Herrera(City of Hope), Shakthi Bhaskar(Vanderbilt University Medical Center), Allison M. Bock(Mayo Clinic), Philippe Armand(Harvard University), Karan Chohan(The University of Texas MD Anderson Cancer Center), Saira Ahmed(The University of Texas MD Anderson Cancer Center), L. Falchi(Memorial Sloan Kettering Cancer Center), Andrew Jallouk(Vanderbilt University Medical Center), Sonja M. Buckley(University of Utah), Reid W. Merryman(Harvard University), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Narendranath Epperla(University of Utah), Sheela Godbole(The Ohio State University Wexner Medical Center), Gilles Salles(Memorial Sloan Kettering Cancer Center), Jennifer L. Crombie(Dana-Farber Cancer Institute), Bo Hu(Central South University), M. Lunning(University of Nebraska Medical Center), Amy Ayers(The University of Texas MD Anderson Cancer Center), Geoffrey Shouse(City Of Hope National Medical Center)
Cited by 1
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
|Advances in Therapy|2017|603
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595